News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
AINU is set to accelerate its expansion footprint, enhance operational capabilities
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
This will be Aster’s fifth hospital in Bengaluru
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Subscribe To Our Newsletter & Stay Updated
